×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IPHA – innate pharma s.a. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IPHA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
01:00 am
ipha
Innate Pharma Releases Its 2025 Financial Calendar
High
Report
Innate Pharma Releases Its 2025 Financial Calendar
11/19
01:05 am
ipha
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501 [Yahoo! Finance]
Low
Report
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501 [Yahoo! Finance]
11/19
01:00 am
ipha
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
Low
Report
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
11/13
03:35 am
ipha
Discover 3 Promising Penny Stocks With Over US$90M Market Cap [Yahoo! Finance]
Medium
Report
Discover 3 Promising Penny Stocks With Over US$90M Market Cap [Yahoo! Finance]
11/13
01:00 am
ipha
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Medium
Report
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
11/12
08:33 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Low
Report
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
11/8
01:00 am
ipha
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
Low
Report
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
11/7
01:00 am
ipha
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Medium
Report
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/24
Innate Pharma Files Its 2019 Universal Registration Document (Document d’enregistrement universel) and Its 2019 Annual Report on Form 20-F
15.1%
1/2 The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia 13.4%
4/14 Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders 6.8%
3/10 Innate Pharma reports FY results [Seeking Alpha] 6.5%
3/3 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.8%
1/31 INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm 3.0%
2/26 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.3%
11/6 Innate Pharma announces preclinical data presentations at SITC 2019 2.2%
11/7 Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting 2.2%
1/13 French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides 2.0%
1/2 The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia 13.4%
4/14 Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders 6.8%
3/10 Innate Pharma reports FY results [Seeking Alpha] 6.5%
3/3 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.8%
1/31 INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm 3.0%
2/26 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.3%
11/6 Innate Pharma announces preclinical data presentations at SITC 2019 2.2%
11/7 Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting 2.2%
1/13 French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides 2.0%
TOP News Decliners
3/14
Innate Pharma SA (IPHYF) CEO Mondher Mahjoubi on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-12.6%
4/23 Innate Pharma S.A. (NASDAQ: IPHA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.8%
1/9 Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial -10.0%
1/2 Innate Pharma's stock rallies 23% on leukemia drug submission in Europe [MarketWatch] -7.6%
12/13 Innate Pharma Provides Update on Lacutamab TELLOMAK Trial -4.4%
2/14 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.3%
1/29 EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A. – IPHA -3.3%
11/13 Innate Pharma third quarter 2019 report -3.1%
12/8 Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019 -3.1%
10/21 Innate Pharma Announces Closing of Global Offering -3.1%
4/23 Innate Pharma S.A. (NASDAQ: IPHA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.8%
1/9 Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial -10.0%
1/2 Innate Pharma's stock rallies 23% on leukemia drug submission in Europe [MarketWatch] -7.6%
12/13 Innate Pharma Provides Update on Lacutamab TELLOMAK Trial -4.4%
2/14 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.3%
1/29 EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A. – IPHA -3.3%
11/13 Innate Pharma third quarter 2019 report -3.1%
12/8 Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019 -3.1%
10/21 Innate Pharma Announces Closing of Global Offering -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: